Status:
COMPLETED
Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease (COPD): The HERMES Study (BY217/M2-125)
Lead Sponsor:
AstraZeneca
Conditions:
Chronic Obstructive Pulmonary Disease (COPD)
Eligibility:
All Genders
40+ years
Phase:
PHASE3
Brief Summary
The aim of the study is to compare the effect of roflumilast on exacerbation rate and pulmonary function in patients with chronic obstructive pulmonary disease (COPD). Roflumilast will be administered...
Eligibility Criteria
Inclusion
- Main
- COPD patients having at least one exacerbation within last year
- FEV1/FVC ratio (post-bronchodilator) ≤ 70%
- FEV1 (post-bronchodilator) ≤ 50% of predicted
- Main
Exclusion
- COPD exacerbation not resolved at first baseline visit
- Diagnosis of asthma and/or other relevant lung disease
Key Trial Info
Start Date :
March 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2008
Estimated Enrollment :
1568 Patients enrolled
Trial Details
Trial ID
NCT00297115
Start Date
March 1 2006
End Date
August 1 2008
Last Update
November 7 2016
Active Locations (287)
Enter a location and click search to find clinical trials sorted by distance.
1
Altana Pharma/Nycomed Investigational Site
Bayou La Batre, Alabama, United States, 36509
2
Altana Pharma/Nycomed Investigational Site
Birmingham, Alabama, United States, 35249
3
Altana Pharma/Nycomed Investigational Site
Birmingham, Alabama, United States, 35294
4
Altana Pharma/Nycomed Investigational Site
Huntsville, Alabama, United States, 35801